People In Brief
Quigley founder leaves after ouster: Guy Quigley resigns effective immediately from his positions as chairman, director, president and CEO of the firm he founded in 1989, following the board's election of dissident shareholder Ted Karkus as chairman. The U.S. District Court for the Eastern District of Pennsylvania rejected Quigley Corp.'s challenges in the wake of the May 20 shareholders meeting, clearing board seats for Karkus and his slate of directors. Karkus was named interim CEO of the Doylestown, Pa.-based firm June 18. Guy Quigley said he was proud Cold-Eeze zinc cold lozenges became "a highly respected product and a well-established household name" over his 20 years at the firm. The board has "the immediate and daunting task of halting the precipitous decline in financial performance" of recent years, Karkus said June 15. Quigley incurred a $2.2 million loss from continuing operations during its fiscal 2009 first quarter as sales fell 24.5 percent (1"The Tan Sheet" May 11, 2009)
More from Archive
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
More from Pink Sheet
Non-Submissions To UK HTA Body Could Increase Unless Commercial Environment Improves, Warns Industry
Finding ways to lower the rebates paid by the pharmaceutical industry to the UK government and fostering partnerships to make the UK a more attractive launch market could help reduce the number of terminated technology appraisals conducted by NICE, the health technology appraisal institute, says the UK pharmaceutical industry.
Blood cancer therapies were most proportionately impacted by the failure of pharmaceutical companies to submit evidence on their cancer therapies to England’s health technology appraisal body, shows analysis by the Pink Sheet.
Employers and other health plan sponsors may need to push for better targeted reforms that lower cost sharing for patients.